Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
一项开放标签扩展研究，旨在评估依那西普生物类似药（LBEC0101）在继续接受依那西普治疗或从原研依那西普转换为LBEC0101治疗的类风湿性关节炎患者中的长期疗效、安全性和免疫原性：一项III期多中心、随机、双盲、平行组研究
期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-019-1910-2
Park, Min-Chan; Matsuno, Hiroaki; Kim, Jinseok; Park, Sung-Hwan; Lee, Sang-Heon; Park, Yong-Beom; Lee, Yun Jong; Lee, Sang-Il; Park, Won; Sheen, Dong Hyuk; Choe, Jung-Yoon; Choi, Chan-Bum; Hong, Seung-Jae; Suh, Chang-Hee; Lee, Shin-Seok; Cha, Hoon-Suk; Yoo, Bin; Hur, Jin-Wuk; Kim, Geun-Tae; Yoo, Wan-Hee; Baek, Han Joo; Shin, Kichul; Shim, Seung Cheol; Yang, Hyung-In; Kim, Hyun Ah; Park, Kyung-Su; Choi, In Ah; Lee, Jisoo; Tomomitsu, Masato; Shin, Seonghye; Lee, Jiyoon; Song, Yeong Wook
